Brief: Poxel Announces Favorable Results For PXl770 Phase 1B Multiple Ascending Dose Trial And Drug-Drug Interaction Study

Poxel SA

18/07/2018 07:07

July 18 (Reuters) - POXEL SA  POXEL.PA :
    * ANNOUNCES FAVORABLE RESULTS FOR PXL770 PHASE 1B MULTIPLE
ASCENDING DOSE TRIAL AND DRUG-DRUG INTERACTION STUDY
    * PXL770 IS ADVANCING INTO A PHASE 2A PROOF-OF-CONCEPT
PROGRAM FOR
NASH
    * DURING H2 2018, PREPARATION FOR PHASE 2A PROGRAM FOR
PXL770 WILL
INCLUDE FILING INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S.
FDA

Source text for Eikon:  ID:nBw14K7pKa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))